blueberry therapeutics limited
blueberry therapeutics limited Company Information
Company Number
07839535
Registered Address
kroll advisory ltd,, the chancery, manchester, greater manchester, M2 1EW
Industry
Research and experimental development on biotechnology
Telephone
01625238776
Next Accounts Due
February 2025
Group Structure
View All
Shareholders
inclin investments inc 14.1%
the gm & cheshire life sciences fund lp 11.5%
View Allblueberry therapeutics limited Estimated Valuation
Pomanda estimates the enterprise value of BLUEBERRY THERAPEUTICS LIMITED at £0 based on a Turnover of £0 and 1.39x industry multiple (adjusted for size and gross margin).
blueberry therapeutics limited Estimated Valuation
Pomanda estimates the enterprise value of BLUEBERRY THERAPEUTICS LIMITED at £0 based on an EBITDA of £-4m and a 5.69x industry multiple (adjusted for size and gross margin).
blueberry therapeutics limited Estimated Valuation
Pomanda estimates the enterprise value of BLUEBERRY THERAPEUTICS LIMITED at £1.3m based on Net Assets of £562.3k and 2.24x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Blueberry Therapeutics Limited Overview
Blueberry Therapeutics Limited is a live company located in manchester, M2 1EW with a Companies House number of 07839535. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in November 2011, it's largest shareholder is inclin investments inc with a 14.1% stake. Blueberry Therapeutics Limited is a established, unknown sized company, Pomanda has estimated its turnover at £0 with unknown growth in recent years.
Upgrade for unlimited company reports & a free credit check
Blueberry Therapeutics Limited Health Check
Pomanda's financial health check has awarded Blueberry Therapeutics Limited a 1 rating. We use a traffic light system to show it exceeds the industry average on 0 measures and has 2 areas for improvement. Company Health Check FAQs
0 Strong
2 Regular
2 Weak
Size
There is insufficient data available for this Key Performance Indicator!
- - Blueberry Therapeutics Limited
- - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- Blueberry Therapeutics Limited
- - Industry AVG
Production
There is insufficient data available for this Key Performance Indicator!
- - Blueberry Therapeutics Limited
- - Industry AVG
Profitability
There is insufficient data available for this Key Performance Indicator!
- - Blueberry Therapeutics Limited
- - Industry AVG
Employees
with 15 employees, this is below the industry average (41)
- - Blueberry Therapeutics Limited
- - Industry AVG
Pay Structure
on an average salary of £89.4k, the company has an equivalent pay structure (£76.1k)
- - Blueberry Therapeutics Limited
- - Industry AVG
Efficiency
There is insufficient data available for this Key Performance Indicator!
- - Blueberry Therapeutics Limited
- - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Blueberry Therapeutics Limited
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - Blueberry Therapeutics Limited
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Blueberry Therapeutics Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 37 weeks, this is average cash available to meet short term requirements (33 weeks)
- - Blueberry Therapeutics Limited
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 65.5%, this is a higher level of debt than the average (51.2%)
- - Blueberry Therapeutics Limited
- - Industry AVG
BLUEBERRY THERAPEUTICS LIMITED financials
Blueberry Therapeutics Limited's latest turnover from May 2023 is 0 and the company has net assets of £562.3 thousand. According to their latest financial statements, Blueberry Therapeutics Limited has 15 employees and maintains cash reserves of £759 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| May 2023 | May 2022 | May 2021 | May 2020 | May 2019 | May 2018 | May 2017 | May 2016 | Nov 2014 | Nov 2013 | Nov 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 0 | 0 | 0 | 0 | 473,738 | 0 | 0 | 0 | 0 | ||
| Other Income Or Grants | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Cost Of Sales | 0 | 0 | 0 | 0 | 117,266 | 0 | |||||
| Gross Profit | 0 | 0 | 0 | 0 | 356,472 | 0 | |||||
| Admin Expenses | 4,015,470 | 3,480,037 | 3,527,485 | 4,908,480 | 3,816,043 | 2,360,585 | |||||
| Operating Profit | -4,015,470 | -3,480,037 | -3,527,485 | -4,908,480 | -3,459,571 | -2,360,585 | -1,652,383 | -1,242,623 | -133,689 | ||
| Interest Payable | 0 | 0 | 0 | 51 | 1,879 | 4,488 | 7,021 | 63,068 | 0 | ||
| Interest Receivable | 10,690 | 115 | 2,391 | 28,128 | 30,266 | 1,486 | 1,446 | 204 | 0 | ||
| Pre-Tax Profit | -4,004,780 | -3,479,922 | -3,525,094 | -4,880,403 | -3,431,184 | -2,363,587 | -1,657,958 | -1,305,487 | -133,689 | ||
| Tax | 701,555 | 684,871 | 1,482,150 | 529,118 | 397,966 | 288,057 | 87,012 | 168,117 | 0 | ||
| Profit After Tax | -3,303,225 | -2,795,051 | -2,042,944 | -4,351,285 | -3,033,218 | -2,075,530 | -1,570,946 | -1,137,370 | -133,689 | ||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Retained Profit | -3,303,225 | -2,795,051 | -2,042,944 | -4,351,285 | -3,033,218 | -2,075,530 | -1,570,946 | -1,137,370 | -133,689 | ||
| Employee Costs | 1,341,392 | 1,387,971 | 1,439,954 | 1,269,672 | 793,455 | 647,526 | 740,183 | 512,388 | 178,692 | ||
| Number Of Employees | 15 | 16 | 16 | 14 | 8 | 7 | 7 | 4 | 4 | ||
| EBITDA* | -3,990,663 | -3,453,978 | -3,496,005 | -4,883,500 | -3,446,567 | -2,346,329 | -1,633,335 | -1,215,043 | -123,313 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| May 2023 | May 2022 | May 2021 | May 2020 | May 2019 | May 2018 | May 2017 | May 2016 | Nov 2014 | Nov 2013 | Nov 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 57,806 | 54,704 | 76,192 | 67,231 | 78,096 | 19,254 | 23,730 | 38,950 | 25,612 | 35,488 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14,762 | 0 | 0 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 57,806 | 54,704 | 76,192 | 67,231 | 78,096 | 19,254 | 23,730 | 38,950 | 40,374 | 35,488 | 0 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 0 | 0 | 0 | 0 | 0 | 135 | 810 | 1,170 | 0 | 8,607 | 6,516 |
| Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Misc Debtors | 812,089 | 763,909 | 721,912 | 110,784 | 393,487 | 77,884 | 57,337 | 134,607 | 7,895 | 0 | 0 |
| Cash | 758,951 | 3,541,826 | 6,211,116 | 4,599,514 | 8,366,160 | 1,214,734 | 1,082,178 | 1,861,410 | 85,657 | 98,872 | 340 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 1,571,040 | 4,305,735 | 6,933,028 | 4,710,298 | 8,759,647 | 1,292,753 | 1,140,325 | 1,997,187 | 93,552 | 107,479 | 6,856 |
| total assets | 1,628,846 | 4,360,439 | 7,009,220 | 4,777,529 | 8,837,743 | 1,312,007 | 1,164,055 | 2,036,137 | 133,926 | 142,967 | 6,856 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 293,595 | 383,629 | 131,238 | 439,365 | 122,077 | 204,924 | 162,105 | 77,275 | 8,917 | 51,059 | 12,690 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 772,960 | 111,294 | 224,915 | 97,572 | 123,789 | 234,576 | 240,187 | 72,106 | 39,121 | 0 | 0 |
| total current liabilities | 1,066,555 | 494,923 | 356,153 | 536,937 | 245,866 | 439,500 | 402,292 | 149,381 | 48,038 | 51,059 | 12,690 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 13,753 | 70,396 | 124,430 | 203,688 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 234,887 | 0 |
| provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 0 | 0 | 0 | 0 | 0 | 13,753 | 70,396 | 124,430 | 203,688 | 234,887 | 0 |
| total liabilities | 1,066,555 | 494,923 | 356,153 | 536,937 | 245,866 | 453,253 | 472,688 | 273,811 | 251,726 | 285,946 | 12,690 |
| net assets | 562,291 | 3,865,516 | 6,653,067 | 4,240,592 | 8,591,877 | 858,754 | 691,367 | 1,762,326 | -117,800 | -142,979 | -5,834 |
| total shareholders funds | 562,291 | 3,865,516 | 6,653,067 | 4,240,592 | 8,591,877 | 858,754 | 691,367 | 1,762,326 | -117,800 | -142,979 | -5,834 |
| May 2023 | May 2022 | May 2021 | May 2020 | May 2019 | May 2018 | May 2017 | May 2016 | Nov 2014 | Nov 2013 | Nov 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||
| Operating Profit | -4,015,470 | -3,480,037 | -3,527,485 | -4,908,480 | -3,459,571 | -2,360,585 | -1,652,383 | -1,242,623 | -133,689 | ||
| Depreciation | 24,807 | 26,059 | 31,480 | 24,980 | 13,004 | 14,256 | 19,048 | 12,818 | 9,599 | 4,049 | 0 |
| Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14,762 | 777 | 777 | 0 |
| Tax | 701,555 | 684,871 | 1,482,150 | 529,118 | 397,966 | 288,057 | 87,012 | 168,117 | 0 | ||
| Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors | 48,180 | 41,997 | 611,128 | -282,703 | 315,468 | 19,872 | -77,630 | 135,777 | -712 | 2,091 | 6,516 |
| Creditors | -90,034 | 252,391 | -308,127 | 317,288 | -82,847 | 42,819 | 84,830 | 77,275 | -42,142 | 38,369 | 12,690 |
| Accruals and Deferred Income | 661,666 | -113,621 | 127,343 | -26,217 | -124,540 | -62,254 | 114,047 | 196,536 | 242,809 | 0 | 0 |
| Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | -2,765,656 | -2,672,334 | -2,805,767 | -3,780,608 | -3,571,456 | -2,097,579 | -1,269,816 | -908,892 | 78,066 | ||
| Investing Activities | |||||||||||
| capital expenditure | |||||||||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | |||||||||||
| Financing Activities | |||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -234,887 | 234,887 | 0 |
| share issue | |||||||||||
| interest | 10,690 | 115 | 2,391 | 28,077 | 28,387 | -3,002 | -5,575 | -62,864 | 0 | ||
| cash flow from financing | 10,690 | 7,615 | 4,457,810 | 28,077 | 10,794,728 | 2,239,915 | 494,412 | 2,836,832 | -76,019 | ||
| cash and cash equivalents | |||||||||||
| cash | -2,782,875 | -2,669,290 | 1,611,602 | -3,766,646 | 7,151,426 | 132,556 | -779,232 | 1,861,410 | -13,215 | 98,532 | 340 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | -2,782,875 | -2,669,290 | 1,611,602 | -3,766,646 | 7,151,426 | 132,556 | -779,232 | 1,861,410 | -13,215 | 98,532 | 340 |
blueberry therapeutics limited Credit Report and Business Information
Blueberry Therapeutics Limited Competitor Analysis
Perform a competitor analysis for blueberry therapeutics limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other established companies, companies in M 2 area or any other competitors across 12 key performance metrics.
blueberry therapeutics limited Ownership
BLUEBERRY THERAPEUTICS LIMITED group structure
Blueberry Therapeutics Limited has no subsidiary companies.
Ultimate parent company
BLUEBERRY THERAPEUTICS LIMITED
07839535
blueberry therapeutics limited directors
Blueberry Therapeutics Limited currently has 4 directors. The longest serving directors include Dr Rita Dobmeyer (Jan 2015) and Mr Adrian Howd (Dec 2019).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Dr Rita Dobmeyer | 64 years | Jan 2015 | - | Director | |
| Mr Adrian Howd | England | 53 years | Dec 2019 | - | Director |
| Mr James Stearns | 45 years | Jul 2023 | - | Director | |
| Mr Marc Shirman | 44 years | Jul 2023 | - | Director |
P&L
May 2023turnover
0
0%
operating profit
-4m
+15%
gross margin
0%
0%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
May 2023net assets
562.3k
-0.85%
total assets
1.6m
-0.63%
cash
759k
-0.79%
net assets
Total assets minus all liabilities
blueberry therapeutics limited company details
company number
07839535
Type
Private limited with Share Capital
industry
72110 - Research and experimental development on biotechnology
incorporation date
November 2011
age
13
incorporated
UK
accounts
Small Company
ultimate parent company
previous names
N/A
last accounts submitted
May 2023
address
kroll advisory ltd,, the chancery, manchester, greater manchester, M2 1EW
accountant
-
auditor
CROWE U.K LLP
blueberry therapeutics limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 3 charges/mortgages relating to blueberry therapeutics limited. Currently there are 1 open charges and 2 have been satisfied in the past.
blueberry therapeutics limited Companies House Filings - See Documents
| date | description | view/download |
|---|
